Michael Okudovich's questions to Mediwound Ltd (MDWD) leadership • Q2 2025
Question
Michael Okudovich of Maxim Group questioned the progress of patient enrollment in the EscharEx VALUE study, the strategic benefit of collaborating with numerous wound care product companies, and which regions are most underserved by current NexoBrid supply.
Answer
CEO Ofer Gonen stated that enrollment is progressing well, with most U.S. sites active and European sites now being activated. EVP Barry Wolfferson added that collaborating with multiple companies demonstrates that EscharEx is effective with any standard-of-care product. Gonen noted that while demand for NexoBrid is substantial across all regions, the company is currently supply-constrained and will have better clarity once the new facility is online.